102 related articles for article (PubMed ID: 29809377)
1. Olanzapine vs. Risperidone in Schizophrenia: A Cross-sectional Comparison of Quality of Life of Caregivers.
Bhargava MS; Rehan HS; Kataria D
Indian J Physiol Pharmacol; 2016 Apr; 60(2):193-199. PubMed ID: 29809377
[TBL] [Abstract][Full Text] [Related]
2. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.
Ritsner M; Gibel A; Perelroyzen G; Kurs R; Jabarin M; Ratner Y
J Clin Psychopharmacol; 2004 Dec; 24(6):582-91. PubMed ID: 15538118
[TBL] [Abstract][Full Text] [Related]
3. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
[TBL] [Abstract][Full Text] [Related]
4. Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.
McGrath BM; Tempier RP
Pharmacopsychiatry; 2005 Jul; 38(4):147-57. PubMed ID: 16025416
[TBL] [Abstract][Full Text] [Related]
5. [Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].
Mayoral F; Montejo AL; Bousoño M; González-Torres MA; Olivares JM; Ros S; Sanjuán J; Escobar R; Lara N
Actas Esp Psiquiatr; 2006; 34(1):7-15. PubMed ID: 16525900
[TBL] [Abstract][Full Text] [Related]
6. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
[TBL] [Abstract][Full Text] [Related]
7. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
Ren XS; Qian S; Lee AF; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2006 Feb; 31(1):57-65. PubMed ID: 16476121
[TBL] [Abstract][Full Text] [Related]
8. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.
van Nimwegen LJ; de Haan L; van Beveren NJ; van der Helm M; van den Brink W; Linszen D
Can J Psychiatry; 2008 Jun; 53(6):400-5. PubMed ID: 18616861
[TBL] [Abstract][Full Text] [Related]
9. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
11. Relationship of quality of life with coping and burden in primary caregivers of patients with schizophrenia.
Kate N; Grover S; Kulhara P; Nehra R
Int J Soc Psychiatry; 2014 Mar; 60(2):107-16. PubMed ID: 23292614
[TBL] [Abstract][Full Text] [Related]
12. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
[TBL] [Abstract][Full Text] [Related]
13. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
[TBL] [Abstract][Full Text] [Related]
14. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.
Ritchie CW; Chiu E; Harrigan S; MacFarlane S; Mastwyk M; Halliday G; Hustig H; Hall K; Hassett A; O'Connor DW; Opie J; Nagalingam V; Snowdon J; Ames D
Int J Geriatr Psychiatry; 2006 Feb; 21(2):171-9. PubMed ID: 16416458
[TBL] [Abstract][Full Text] [Related]
17. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
[TBL] [Abstract][Full Text] [Related]
18. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
19. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Keefe RS; Young CA; Rock SL; Purdon SE; Gold JM; Breier A;
Schizophr Res; 2006 Jan; 81(1):1-15. PubMed ID: 16202565
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.
Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB
Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
